|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
61,890,000 |
Market
Cap: |
N/A |
Last
Volume: |
2,615,875 |
Avg
Vol: |
1,187,095 |
52
Week Range: |
$7.07 - $7.07 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Related Products |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Cundy Kenneth C |
SVP, Preclinical Development |
|
2008-07-23 |
4 |
AS |
$44.50 |
$44,508 |
D/D |
(1,000) |
10,198 |
|
- |
|
Cundy Kenneth C |
SVP, Preclinical Development |
|
2008-07-23 |
4 |
OE |
$1.50 |
$1,500 |
D/D |
1,000 |
11,198 |
|
- |
|
Harris William G |
SVP, Finance and CFO |
|
2008-07-23 |
4 |
AS |
$45.00 |
$22,500 |
D/D |
(500) |
33,782 |
|
- |
|
Gallop Mark A |
SVP, Research |
|
2008-07-14 |
4 |
AS |
$40.06 |
$40,157 |
I/I |
(1,000) |
132,253 |
|
- |
|
Cundy Kenneth C |
SVP, Preclinical Development |
|
2008-07-01 |
4 |
AS |
$37.78 |
$38,096 |
D/D |
(1,000) |
10,198 |
|
- |
|
Cundy Kenneth C |
SVP, Preclinical Development |
|
2008-07-01 |
4 |
OE |
$1.50 |
$1,500 |
D/D |
1,000 |
11,198 |
|
- |
|
Gallop Mark A |
SVP, Research |
|
2008-07-01 |
4 |
AS |
$37.78 |
$76,174 |
I/I |
(2,000) |
133,253 |
|
- |
|
Harris William G |
SVP, Finance and CFO |
|
2008-07-01 |
4 |
AS |
$37.78 |
$38,084 |
D/D |
(1,000) |
34,282 |
|
- |
|
Berns Paul L |
Director |
|
2008-06-16 |
4 |
AS |
$42.00 |
$525,205 |
D/D |
(12,500) |
0 |
|
- |
|
Berns Paul L |
Director |
|
2008-06-16 |
4 |
OE |
$12.86 |
$160,750 |
D/D |
12,500 |
12,500 |
|
- |
|
Harris William G |
SVP, Finance and CFO |
|
2008-06-02 |
4 |
AS |
$41.61 |
$41,865 |
D/D |
(1,000) |
35,282 |
|
- |
|
Gallop Mark A |
SVP, Research |
|
2008-06-02 |
4 |
AS |
$41.60 |
$113,028 |
I/I |
(2,700) |
135,553 |
|
- |
|
Gallop Mark A |
SVP, Research |
|
2008-06-02 |
4 |
AS |
$41.92 |
$12,588 |
I/I |
(300) |
135,253 |
|
- |
|
Cundy Kenneth C |
SVP, Preclinical Development |
|
2008-06-02 |
4 |
AS |
$41.65 |
$41,866 |
D/D |
(1,000) |
10,198 |
|
- |
|
Cundy Kenneth C |
SVP, Preclinical Development |
|
2008-06-02 |
4 |
OE |
$1.50 |
$977 |
D/D |
651 |
11,198 |
|
- |
|
Cundy Kenneth C |
SVP, Preclinical Development |
|
2008-05-14 |
4 |
AS |
$44.04 |
$44,040 |
D/D |
(1,000) |
9,945 |
|
- |
|
Harris William G |
SVP, Finance and CFO |
|
2008-05-14 |
4 |
AS |
$45.06 |
$22,530 |
D/D |
(500) |
36,210 |
|
- |
|
Freund John Gordon |
Director |
|
2008-05-13 |
4 |
B |
$43.59 |
$4,228,065 |
I/I |
97,000 |
1,058,257 |
2.1 |
- |
|
Freund John Gordon |
Director |
|
2008-05-12 |
4 |
B |
$43.23 |
$6,354,774 |
I/I |
147,008 |
961,257 |
2.1 |
- |
|
Savello David R |
SVP, Development |
|
2008-05-12 |
4 |
S |
$42.70 |
$479,480 |
D/D |
(11,192) |
14,540 |
|
- |
|
Barrett Ronald W |
Chief Executive Officer |
|
2008-05-09 |
4 |
GD |
$0.00 |
$0 |
I/I |
1,190 |
69,596 |
|
- |
|
Freund John Gordon |
Director |
|
2008-05-09 |
4 |
B |
$40.35 |
$4,411,286 |
I/I |
109,325 |
814,249 |
2.1 |
- |
|
Harris William G |
SVP, Finance and CFO |
|
2008-05-01 |
4 |
AS |
$42.27 |
$42,592 |
D/D |
(1,000) |
36,710 |
|
- |
|
Cundy Kenneth C |
SVP, Preclinical Development |
|
2008-05-01 |
4 |
AS |
$42.27 |
$42,607 |
D/D |
(1,000) |
10,945 |
|
- |
|
Gallop Mark A |
SVP, Research |
|
2008-05-01 |
4 |
AS |
$42.43 |
$8,496 |
I/I |
(200) |
138,253 |
|
- |
|
663 Records found
|
|
Page 18 of 27 |
|
|